Skip to main content
OpenTrials
Completed

NCT Number: NCT02821104

Complement and Cardiovascular Risk in Adolescents

This study evaluates how genetic variations in complement, a part of the immune system, affect cardiovascular risk in adolescents.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Cardiometabolic diseases usually do not produce significant mortality and morbidity until adulthood. There is clear evidence, however, that these diseases have their origins in childhood and adolescence. With the rising incidence of obesity associated with poorer eating and less physical activity in children and adolescents it is important that the investigators study these diseases early in their course if the investigators are to prevent future cardiometabolic disease. While obesity clearly increases cardiometabolic risk, not all obese subjects are at increased risk; approximately 25-30% of obese adults and adolescents are metabolically healthy. The complement system is key physiological component in controlling inflammation and recent studies have indicated complement plays an important role in increasing obesity and cardiometabolic risk. Adults with proven cardiometabolic disease or at future risk for cardiometabolic disease have increased levels of the complement components C3, C3a-desArg, and C4 compared to healthy, not at risk, control subjects, independent of obesity. Increased C3 or C3a-desArg levels in adolescents are associated with increased cardiometabolic risk independent of obesity. Two specific single nucleotide polymorphisms (SNPs) in the intron for C3, rs11569562 and rs2250656, both with A>G polymorphisms, are associated with increased serum C3 levels, and increases in a variety of cardiovascular risk factors. No one has investigated how C3 polymorphisms affect risk factors in adolescents. The C4 gene has significant copy number variation and increased copy number is associated with increased C4 levels. The relationship of C4 gene copy number to cardiometabolic risk has not been studied in adults or adolescents. The short-term objectives of this study are to explore differences in cardiometabolic risk factors in overweight and obese adolescents with C3 polymorphisms and also to explore how C4 gene copy number variation affects risk factors. The investigators overall hypothesis is that variations in C3 polymorphisms, C4 gene copy number or both will have significant impact on cardiometabolic health in overweight and obese adolescents. Both traditional and nontraditional cardiometabolic risk markers, including measures of body habitus, blood pressure, lipids, vascular function, insulin secretion and sensitivity, inflammation, and clotting will be investigated in 100 overweight and obese adolescents. The investigators proposed study will help us understand the role of complement and its genetics in the development of cardiometabolic risk and in potentially developing genetic biomarkers for adolescents at increased risk.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adolescents age 12 to 18 years
  • Medication free for 2 weeks except oral contraceptives in females
  • Non Hispanic white

Exclusion criteria

  • Chronic medications except for contraceptives in females.
  • History of autoimmune disease either endocrine or connective tissue type
  • History of hematologic or renal disease, malignancy or other chronic disease
  • Hispanic ethnicity,
  • African-American or Asian race

Treatment and study plan

Primary outcomes

  1. Complement C3 Genotype

    Time frame: Baseline

    Genetic C3F genotype allele presence

  2. C4 Copy Number

    Time frame: Baseline

    C4A or C4B gene copy numbers

Secondary outcomes

  1. BMI

    Time frame: Baseline

    Body mass index

  2. Waist Circumference

    Time frame: Baseline

    Waist circumference at narrowest point

  3. Body Fat

    Time frame: Baseline

    Percent body fat BodPod

  4. Endothelial Function

    Time frame: 8 min

    reactive hyperemia response to upper arm occlusion

  5. Vascular Stiffness

    Time frame: baseline

    augmentation index of reflected blood pressure wave

  6. Endothelin 1

    Time frame: baseline

  7. Inflammation

    Time frame: baseline

    IL6

  8. Clotting

    Time frame: baseline

    PAI1

  9. Insulin Sensitivity

    Time frame: baseline

    Oral glucose tolerance test

Sponsors and collaborators

Lead sponsor

Ohio State University

Other

Collaborators

  • American Heart Association

Registry information

Acronym: CCRIA

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jul 1, 2016
Registry last updated
Jun 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.